Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations. These fundamentals include a revamped market access process, a high-quality yet affordable manufacturing base, and a budding reputation as one of the best clinical trials destinations on the continent.

Other topics touched on in this report include Spain’s booming biotech scene, the internationalization efforts of the country’s well-established mid-cap firms, a private healthcare market growing in both size and importance, and the nation’s expertise in oncology.